Drug insight: bleeding after percutaneous coronary intervention-risks, measures and impact of anticoagulant treatment options (Q33369119)

26 July 2017

1 reference

title

Drug insight: bleeding after percutaneous coronary intervention-risks, measures and impact of anticoagulant treatment options (English)

1 reference

26 July 2017

1 reference

1 reference

Martin T Rothman

1

1 reference

26 July 2017

publication date

1 September 2005

1 reference

Nature Clinical Practice Cardiovascular Medicine

26 July 2017

published in

1 reference

26 July 2017

volume

2

1 reference

26 July 2017

issue

9

1 reference

26 July 2017

page(s)

465-474

1 reference

Beyond heparin and aspirin: new treatments for unstable angina and non-Q-wave myocardial infarction

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

Practice patterns and outcomes of percutaneous coronary interventions in the United States: 1995 to 1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

Bivalirudin in PCI: an overview of the REPLACE-2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

Description of modern practices of percutaneous coronary intervention and identification of risk factors for adverse outcome in the French nationwide OPEN registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

Arterial puncture closing devices compared with standard manual compression after cardiac catheterization: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

Radial versus femoral approach for percutaneous coronary diagnostic and interventional procedures; Systematic overview and meta-analysis of randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

Antithrombotic therapy in patients undergoing percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

Low-molecular-weight heparin vs. unfractionated heparin in percutaneous coronary intervention: a combined analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

Complications from heparin-induced thrombocytopenia in patients undergoing cardiopulmonary bypass

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

Efficacy and safety of abciximab on acute myocardial infarction treated with percutaneous coronary interventions: a meta-analysis of randomized, controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

P2Y12, a new platelet ADP receptor, target of clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

Preclinical and clinical studies with selective reversible direct P2Y12 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

Use of direct thrombin inhibitors in acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

Clinical outcomes of bivalirudin for ischemic heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

Abciximab as Adjunctive Therapy to Reperfusion in Acute ST-Segment Elevation Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

7 January 2021

Clinical challenges of bleeding in percutaneous coronary intervention.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

7 January 2021

Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

7 January 2021

Comparison of transradial and transfemoral approaches for coronary angiography and angioplasty in octogenarians (the OCTOPLUS study)

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

7 January 2021

Stenting in acute coronary syndromes: a comparison of radial versus femoral access sites

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

7 January 2021

Economic impact of bleeding complications and the role of antithrombotic therapies in percutaneous coronary intervention.

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

7 January 2021

Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor II

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

7 January 2021

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

1 reference

7 January 2021

Patterns of use of heparins in ACS. Correlates and hospital outcomes: the Global Registry of Acute Coronary Events (GRACE)

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

7 January 2021

Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events

1 reference

https://api.crossref.org/works/10.1038%2FNCPCARDIO0311

7 January 2021

Identifiers

DOI

10.1038/NCPCARDIO0311

1 reference

Dimensions Publication ID

26 July 2017

1053483869

0 references

1 reference